Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gatifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.89 |
| ▸ | HPGD | P15428 | 6/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.89 |
| ▸ | POLB | P06746 | 2/20 | 0.89 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.89 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.89 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.89 |
| ▸ | CLK2 | P49760 | 1/20 | 0.89 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Gatifloxacin SCHEMBL30910969 | 0.94 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10KCNH2 | |
| Gatifloxacin SCHEMBL2224369 | 0.94 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10KCNH2 | |
| (S)-Gatifloxacin SCHEMBL22592 | 0.94 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10KCNH2 | |
| Gatifloxacin SCHEMBL22591 | 0.94 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10KCNH2 | |
| Gatifloxacin SCHEMBL29356306 | 0.94 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10KCNH2 | |
| (R)-Gatifloxacin SCHEMBL5670068 | 0.94 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10KCNH2 | |
| (S)-Gatifloxacin SCHEMBL4818160 | 0.94 | KDM4E (0.98) | KDM4EHPGDALDH1A1HSD17B10KCNH2 | |
| Gatifloxacin SCHEMBL1380256 | 0.94 | KDM4E (0.98) | KDM4EHPGDALDH1A1HSD17B10KCNH2 | |
| (S)-Gatifloxacin SCHEMBL3565686 | 0.94 | KDM4E (0.98) | KDM4EHPGDALDH1A1HSD17B10KCNH2 | |
| Gatifloxacin SCHEMBL3565683 | 0.94 | KDM4E (0.98) | KDM4EHPGDALDH1A1HSD17B10KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423153-B2 | Forms A, B, C, D, E1, F, G, H, I, and J; preparing forms omega and T2RP. | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-09-09 | — | — | US | disclosed |
| EP-1645274-A1 | Process for making gatifloxacin form omega | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-04-12 | — | — | EP | disclosed |
| US-20050288301-A1 | Novel crystalline forms of gatifloxacin | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS. | 2005-12-29 | — | — | US | disclosed |
| US-20050288302-A1 | Novel crystalline forms of gatifloxacin | NIDDAM-HILDESHEIM VALERIE | 2005-12-29 | — | — | US | disclosed |
| EP-1503762-A2 | NOVEL CRYSTALLINE FORMS OF GATIFLOXACIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-02-09 | — | — | EP | disclosed |
| US-20040009989-A1 | Novel crystalline forms of gatifloxacin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-01-15 | — | — | US | disclosed |
| WO-2003094919-A2 | NOVEL CRYSTALLINE FORMS OF GATIFLOXACIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288302-A1 | Novel crystalline forms of gatifloxacin | RECQL, GATD3, CYP2F1 | KDM4E 4328/4885HPGD 1380/4885ALDH1A1 3892/4885 |
| US-20050288301-A1 | Novel crystalline forms of gatifloxacin | RECQL, GATD3, CYP2F1 | KDM4E 4328/4885HPGD 1380/4885ALDH1A1 3892/4885 |
| US-20040009989-A1 | Novel crystalline forms of gatifloxacin | RECQL, GATD3, CYP2F1 | KDM4E 4328/4885HPGD 1380/4885ALDH1A1 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.